Generate:Biomedicines
Generative-AI protein design company (Flagship) that went public in 2026 and is testing an antibody that neutralises leaked ADC payload to reduce side effects.
Generate:Biomedicines went public in early 2026 (~$400M IPO). Oncology programmes: GB-4362, an MMAE neutraliser with FDA Fast Track for enfortumab vedotin toxicity in urothelial cancer (trial-in-progress at ESMO 2026), and GB-5267, a MUC16 CAR-T with Roswell Park. First AI-designed antibody advanced to phase 3 in a non-oncology indication.
Pages like this
not linked directly; found by shared links- CompanyIsomorphic Labs
Shares AI-designed proteins that grip the floppy parts of cancer drivers, De novo designed protein binders, AI-driven drug & target discovery, The valley of death between lab and product and the tag frontier.
- CompanyArsenal Biosciences
Shares Ovarian cancer, CAR-T cell therapy and the tag frontier.
- CompanyAktis Oncology
Shares Bladder & urothelial cancer and the tag frontier.
- TechnologySystematic drug repurposing
Shares AI-driven drug & target discovery and the tag frontier.
- TechnologyTrained innate immunity
Shares Bladder & urothelial cancer and the tag frontier.
- TechnologyArmoured, logic-gated & next-gen CARs
Shares CAR-T cell therapy and the tag frontier.
- TechnologyBispecific ADC
Shares Bladder & urothelial cancer and the tag frontier.
- TechnologyCAR-NK & CAR-macrophage
Shares CAR-T cell therapy and the tag frontier.